Literature DB >> 28722607

Mucosal leishmaniasis: A Retrospective Study of 327 Cases from an Endemic Area of Leishmania (Viannia) braziliensis.

Carolina Cincurá1,2, Clara Mônica F de Lima1,2, Paulo R L Machado1,2, Jamary Oliveira-Filho1, Marshall J Glesby3, Marcus M Lessa1,2, Edgar M Carvalho4,1,2.   

Abstract

Mucosal leishmaniasis (ML) is observed only in about 3% of patients with American tegumentary leishmaniasis (ATL) but has a high potential for destructive, disfiguring, and disabling sequelae. Prior reports of clinical and epidemiologic features of ML are limited by small numbers of cases. In this study, we evaluated changes in the demographic features and clinical presentation of ML in an endemic area of Leishmania braziliensis transmission over a period of 20 years. The charts of 327 patients with ML diagnosed between 1995 and 2014 were reviewed. The majority of patients (67%) were male. Age ranged from 8 months to 103 years, with a median age of 38.5 years (interquartile range: 22-58 years). The greatest number of patients was between 19 and 39 years (31%). Over the study period, there was an increase in patients with ML more than 60 years of age, an increase in ML with concomitant cutaneous lesions, a decrease in the period of time between the documentation of cutaneous lesions and the diagnosis of mucosal disease, and an increase in the frequency of patients presenting with stage I and V of ML. Moreover, there was a positive correlation between severity of mucosal disease and both age and the period of time between cutaneous lesion and mucosal disease. Response to therapy of ML remained similar over a period of 20 years. Despite the improvement in medical care during the study period, the prevalence of ML did not change and severe disease continues to be a major challenge for the management of these patients.

Entities:  

Mesh:

Year:  2017        PMID: 28722607      PMCID: PMC5590558          DOI: 10.4269/ajtmh.16-0349

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  22 in total

1.  Epidemiological and clinical changes in American tegumentary leishmaniasis in an area of Leishmania (Viannia) braziliensis transmission over a 20-year period.

Authors:  Lara Jirmanus; Marshall J Glesby; Luiz H Guimarães; Ednaldo Lago; Maria Elisa Rosa; Paulo R Machado; Edgar M Carvalho
Journal:  Am J Trop Med Hyg       Date:  2012-03       Impact factor: 2.345

2.  [El Niño episodes and temporal distribution of kala azar on São Luís island, Maranhão State, Brazil].

Authors:  José M M Rebêlo
Journal:  Cad Saude Publica       Date:  2008-07       Impact factor: 1.632

3.  Concomitant early mucosal and cutaneous leishmaniasis in Brazil.

Authors:  Viviane S Boaventura; Virginia Cafe; Jackson Costa; Fabiano Oliveira; Andre Bafica; Andrea Rosato; Luiz A R de Freitas; Claudia Brodskyn; Manoel Barral-Netto; Aldina Barral
Journal:  Am J Trop Med Hyg       Date:  2006-08       Impact factor: 2.345

4.  Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis.

Authors:  Annette Ives; Catherine Ronet; Florence Prevel; Giulia Ruzzante; Silvia Fuertes-Marraco; Frederic Schutz; Haroun Zangger; Melanie Revaz-Breton; Lon-Fye Lye; Suzanne M Hickerson; Stephen M Beverley; Hans Acha-Orbea; Pascal Launois; Nicolas Fasel; Slavica Masina
Journal:  Science       Date:  2011-02-11       Impact factor: 47.728

5.  Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis.

Authors:  Paulo R L Machado; Hélio Lessa; Marcus Lessa; Luiz H Guimarães; Heejung Bang; John L Ho; Edgar M Carvalho
Journal:  Clin Infect Dis       Date:  2007-02-02       Impact factor: 9.079

6.  Multiclonal Leishmania braziliensis population structure and its clinical implication in a region of endemicity for American tegumentary leishmaniasis.

Authors:  A Schriefer; A L F Schriefer; A Góes-Neto; L H Guimarães; L P Carvalho; R P Almeida; P R Machado; H A Lessa; A Ribeiro de Jesus; L W Riley; E M Carvalho
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Age modifies the immunologic response and clinical presentation of American tegumentary leishmaniasis.

Authors:  Augusto M Carvalho; Camila F Amorim; Juliana L S Barbosa; Alexsandro S Lago; Edgar M Carvalho
Journal:  Am J Trop Med Hyg       Date:  2015-04-27       Impact factor: 2.345

8.  Clinical and immunopathological aspects of disseminated cutaneous leishmaniasis.

Authors:  E M Carvalho; A Barral; J M Costa; A Bittencourt; P Marsden
Journal:  Acta Trop       Date:  1994-04       Impact factor: 3.112

9.  A proposed new clinical staging system for patients with mucosal leishmaniasis.

Authors:  Hélio A Lessa; Marcus M Lessa; Luiz Henrique Guimarães; Clara Mônica F Lima; Sergio Arruda; Paulo R Machado; Edgar M Carvalho
Journal:  Trans R Soc Trop Med Hyg       Date:  2012-05-11       Impact factor: 2.184

10.  Further Evidence of an Association between the Presence of Leishmania RNA Virus 1 and the Mucosal Manifestations in Tegumentary Leishmaniasis Patients.

Authors:  Lilian Motta Cantanhêde; Cipriano Ferreira da Silva Júnior; Marcos Massayuki Ito; Kátia Paula Felipin; Roberto Nicolete; Juan Miguel Villalobos Salcedo; Renato Porrozzi; Elisa Cupolillo; Ricardo de Godoi Mattos Ferreira
Journal:  PLoS Negl Trop Dis       Date:  2015-09-15
View more
  11 in total

1.  Treatment of Bolivian Leishmania braziliensis Cutaneous and Mucosal Leishmaniasis.

Authors:  Jaime Soto; Patricia Gutiérrez; Paula Soto; David Paz; Eduardo Cayhuara; Carmen Molina; Mia Sánchez; Jonathan Berman
Journal:  Am J Trop Med Hyg       Date:  2022-01-24       Impact factor: 2.345

2.  Imported cases of cutaneous leishmaniasis in Cuba, 2017: role of human movement.

Authors:  Lianet Monzote; Daniel González; Orestes Blanco; Jorge Fraga; Virginia Capó; Alberto Herrera; Ana Margarita Montalvo
Journal:  Trop Dis Travel Med Vaccines       Date:  2022-07-01

3.  Case Report: Mucosal Leishmaniasis in New York City.

Authors:  Henry W Murray; Daniel P Eiras; Laura A Kirkman; Raymond L Chai; Daniel Caplivski
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

4.  Differentiation of mucosal lesions in mucocutaneous leishmaniasis and paracoccidioidomycosis.

Authors:  Creuza Rachel Vicente; Aloisio Falqueto
Journal:  PLoS One       Date:  2018-11-26       Impact factor: 3.240

5.  Distribution, treatment outcome and genetic diversity of Leishmania species in military personnel from Colombia with cutaneous leishmaniasis.

Authors:  Camilo A Correa-Cárdenas; Julie Pérez; Luz H Patino; Juan David Ramírez; Maria Clara Duque; Yanira Romero; Omar Cantillo-Barraza; Omaira Rodríguez; Maria Teresa Alvarado; Claudia Cruz; Claudia Méndez
Journal:  BMC Infect Dis       Date:  2020-12-09       Impact factor: 3.090

Review 6.  Protection and Pathology in Leishmania braziliensis Infection.

Authors:  Augusto M Carvalho; Olívia Bacellar; Edgar M Carvalho
Journal:  Pathogens       Date:  2022-04-14

7.  Case Report: Successful Treatment with Miltefosine of Severe New World Mucosal Leishmaniasis Caused by Leishmania guyanensis.

Authors:  Manuel Calvopina; Sara Jijon; Esteban Serrano; Hirotomo Kato
Journal:  Am J Trop Med Hyg       Date:  2020-06-04       Impact factor: 2.345

8.  Case Report: Unusual Presentation of Pharyngeal Mucosal Leishmaniasis due to Leishmania (Viannia) braziliensis.

Authors:  Lorena Pinheiro Figueiredo; Laiana do Carmo Almeida; Andréa Magalhães; Sérgio Arruda; Marcus M Lessa; Edgar M Carvalho
Journal:  Am J Trop Med Hyg       Date:  2020-10       Impact factor: 3.707

9.  Successful treatment by adding thalidomide to meglumine antimoniate in a case of refractory anthroponotic mucocutaneous leishmaniasis.

Authors:  Vahid Mashayekhi Goyonlo; Sadegh Vahabi-Amlashi; Faezeh Taghavi
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-08-27       Impact factor: 4.077

Review 10.  Leishmania Protein Kinases: Important Regulators of the Parasite Life Cycle and Molecular Targets for Treating Leishmaniasis.

Authors:  Antonia Efstathiou; Despina Smirlis
Journal:  Microorganisms       Date:  2021-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.